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Myocardial infarctionAbstract Background and aim: Glycosylated hemoglobin (HbA1c) is a more stable and accurate
parameter of the glycometabolic state than fasting glycemia. However, its role in predicting the
prognosis in acute myocardial infarction patients remains unclear with conflicting results from
the available data. This study evaluates the effect of admission HbA1c as a parameter of the gly-
cometabolic state on the clinical outcome in non diabetic acute st segment elevation myocardial
infarction (STEMI) patients.
Method: Between June 2012 and December 2014, 208 consecutive STEMI non diabetic patients
who underwent primary percutaneous coronary intervention (PPCI) were enrolled. Patients were
divided according to the HbA1c level into 2 groups 112 patients in group I (HbA1c 6 5.6%) and
96 patients in group II (HbA1c 5.7–6.4%). In hospital and at 6 months major adverse cardiac out-
come (MACE) was calculated.
Results: Mean age was 55.9 ± 7.12 years, 149 were men and there was no significant difference
regarding baseline characteristics. Post PPCI TIMI III flow was higher in group I (p= 0.016),
angiographic no reflow was higher in group 2 (p= 0.003). No significant difference regarding in
hospital MACE (p= 0.44). At 6 month follow up MACE was significantly higher in group 2
(p< 0.001) and this mainly due to higher incidence of target lesion revascularization (TLR) in
group 2 (p< 0.001). Multivariate analysis showed that HbA1c is significantly associated with
6 months MACE (hazard ratio 1.9; p= 0.022).
Conclusion: Abnormal glycometabolic state assessed by HbA1c at admission in non diabetic
STEMI patients was associated with higher MACE incidence at 6 months follow up.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glycosylated hemoglobin (HbA1c) is a stable marker of long
term blood glucose control and reflects the average blood glu-
cose concentrations over the previous 8–12 weeks [1]. Elevated
74 S. Samir, M. NaseemHbA1c is associated with increased cardiovascular risk. It is
more closely related to the risk of complications than the other
single or episodic measures of glucose levels in diabetic
patients [2–5]. In a recent large based population study, it
was found that the small elevation in the level of HbA1c in
non diabetic patients (i.e. HbA1c < 6.5%), is associated with
increased risk of coronary heart disease (CHD) in apparently
healthy non diabetic patients irrespective of the fasting blood
glucose level [6]. According to the American Diabetes Associ-
ation (ADA), HbA1c levels between 5.7% and 6.4% indicates
prediabetic state [7].
Acute myocardial infarction (AMI) is associated with high
risk mortality and morbidity even with the best reperfusion
strategy [8]. Stratification of high risk patients is important
to improve the prognosis. Previous trials have shown that
admission blood glucose had short and long term prognostic
value in AMI patients [9,10]. However; the admission blood
glucose can’t reflect the true glycometabloic state as it is
affected by catecholamine release, stress and the patient’s last
meal. Data on the prognostic role of HbA1c in patients with
AMI are derived from studies which differ in patients’ selec-
tion criteria and therapy (thrombolysis vs. mechanical revascu-
larization). Primary percutaneous coronary intervention
(PPCI) has shown significant beneficial protection against
death or reinfarction within 6 months AMI [11].
Therefore, we aimed in this study to investigate whether the
glycometabolic state measured by the level of HbA1c at time
of admission could have a prognostic value for the angio-
graphic and short term clinical outcome in STEMI non dia-
betic patients undergoing PPCI and whether there is a
difference between subgroups of non diabetic patients based
on the level of HbA1c.2. Material and methods
2.1. Patient population
This is a single center observational prospective study. The
study included 208 consecutive patients presented by STEMI
to the cardiology department of Tanta university hospital dur-
ing the period from June 2012 to December 2014. All the
patients underwent PPCI. The study included males and
females aged between 18 and 75 years who have the diagnostic
criterion of STEMI i.e. persistent typical chest pain more than
30 min and P2 mm ST segment elevation in 2 contiguous
ECG leads within 12 h of symptom onset. Exclusion criteria
included previous use of hypoglycemic drugs or insulin, admis-
sion HbA1cP 6.5%, symptoms more than 12 h, carcinogenic
shock and unsuitable coronary anatomy for PCI. The patients
were divided into 2 groups based on the level of admission
HbA1c according to the ADA guideline, group I
(HbA1c 6 5.6%) and group II (HbA1c 5.7–6.4%). A written
informed consent was obtained from all participants. The pro-
tocol was approved by the local ethics committee.
2.2. Patients’ data
Baseline characteristics and demographic data were obtained
for all patients. Vital signs, laboratory data and previous dis-
ease history were recorded.2.3. Glycated hemoglobin measurements
Blood samples (5 lL of Capillary blood or anticoagulated
venous blood) were obtained at the time of admission and
tested with NycoCard Reader II manufactured by Axis-
Shield that reports Diabetes Control and Complications Trial
(DCCT) aligned values [12] and using National Glycohe-
moglobin Standardization Program (NGSP)-certified method
[13].
2.4. Pharmacotherapy
All the patients received the following regimen before PPCI:
(1) clopidogrel loading dose of 600 mg orally, followed by a
maintenance dose of 75 mg/day; (2) Aspirin 300 mg followed
by 81–325 mg/day; (3) During the procedure, intravenous
unfractionated heparin (70 IU/kg), the dose is increased to
100 IU/kg in case glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors
are not administrated; and (4) GPIIb/IIIa inhibitor (eptifi-
batide or tirofiban) unless contraindicated.
2.5. Angiographic procedure
Coronary angiography and PPCI were done through femoral
approach. The use of aspiration thrombectomy device was left
upon the operator’s discretion and only infarct related artery
was treated during the index procedure. Pain to balloon time;
TIMI flow rate [14] before and after the procedure; and
myocardial brush grade (MBG) [15] were assessed.
2.6. In hospital outcome and follow up
MACE was defined as cardiac death, acute myocardial infarc-
tion, stent thrombosis or target lesion revascularization (TLR).
Academic Research Consortium definition was used to diag-
nose and grade stent thrombosis [16]. TLR was defined as clin-
ically indicated percutaneous or surgical revascularization of
the index lesion during follow-up. Revascularization was con-
sidered clinically indicated if there was >70% diameter steno-
sis on angiography or >50% stenosis together with a positive
stress test or ischemic symptoms.
Transthoracic echocardiography evaluations were per-
formed after 48–72 h of acute myocardial infarction. Echocar-
diographic measurements of the left ventricle volumes and
ejection fraction (EF%)were performed according to recom-
mendations of the American Society of echocardiography
[17]. Upon discharge, all patients were on optimal medical
therapy including dual antiplatelet, beta blocker, statin and
angiotensin converting enzyme inhibitors (ACEI). Clinical fol-
low up was conducted through office visits and telephone con-
tact during the 6 month follow up period.
2.7. Statistical analysis
The data were analyzed statistically using SPSS version 16.
Quantitative variables were presented in the form of mean
and standard deviation and description of qualitative vari-
ables was presented in their absolute and relative frequen-
cies. Comparison between quantitative variables was
carried out by T test of two independent samples and Chi
Table 1 Baseline characteristics and laboratory findings.
Characteristics (total = 208) Group 1 (n= 112) Group 2 (n= 96) p
Sex
Male 77 (68.75%) 72 (75.0%) 0.399
Female 35 (31.25%) 24 (25.0%)
Age (mean) 55.44 ± 5.87 56.5 ± 6.8 0.2289
Smoking 42 (37.5%) 49 (51.0%) 0.068
Hypertension 21 (18.75%) 20 (20.8%) 0.419
Family history of CAD 30 (26.79%) 27 (28.1%) 0.475
Hypercholesterolemia 46 (41.07%) 50 (52.1%) 0.126
Previous MI 26 (23.21%) 30 (31.0%) 0.126
eGFR< 60 ml 16 (14.29%) 22 (23.0%) 0.149
Killip class > 1 6 (5.4%) 4 (4.5%) 0.435
BMI (kg/m2) 26.84 ± 4.57 27.9 ± 4.3 0.088
Fasting blood sugar (mg/dl) 106.55 ± 11.8 108.4 ± 12.1 0.266
TC (mg/dl) 189.7 ± 30.84 199 ± 38.9 0.056
Triglycerides (mg/dl) 193.87 ± 37.24 202.1 ± 39.7 0.124
Serum creatinine (mg/dl) 0.91 ± 0.39 0.93 ± 0.76 0.807
Hemoglobin level (gm) 12.8 ± 1.7 12.6 ± 1.3 0.941
Ejection fraction (EF%) 50.3 ± 9 48.7 ± 8 0.324
Troponin (ng/ml) 4.69 + 1.77 5.09 + 1.62 0.092
Values are n (%). BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction;
TC, total cholesterol.








281.25 ± 120.36 275.38 ± 92.03 0.697
Left main or three vessels 20 (17.8%) 23 (21.9) 0.354
Syntax score mean ± SD 11.1 ± 4.2 12 ± 8.07 0.137
Infarct related artery LAD 71 (63.39%) 58 (60%) 0.383
CX 19 (16.96%) 20 (21%) 0.296
RCA 20 (17.86%) 18 (19%) 0.504
Thrombus aspiration 35 (31.25%) 35 (36%) 0.259
GPIIb/IIIa 88 (78.57%) 72 (75%) 0.328
DES 15 (13.30%) 11 (11.40)% 0.418
Stent utilization 106 (94.60)% 90 (93.70)% 0.506
RD Mean ± SD 3.04 ± 0.38 2.97 ± 0.28 0.137
STENT diameter
Mean ± SD
3.02 ± 0.35 2.96 ± 0.27 0.173
STENT length
Mean ± SD
22.09 ± 5.64 20.70 ± 5.91 0.084
TIMI III after 98 (87.5%) 72 (75%) 0.016
MBG II or III 79 (70.5%) 54 (55%) 0.003
Angiographic no reflow 8 (7.14%) 19 (19.7%) 0.006
Values are n (%). CX, circumflex; DES, drug eluting stent; GPIIb/IIIa, glycoprotein IIb/IIIa; LAD, left anterior descending; MBG, myocardial
blush grade; RCA, right coronary artery; RD, reference diameter; TIMI, thrombolysis in myocardial infarction.
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each other. A backward stepwise multivariate Cox regres-
sion analysis was performed to identify independent predic-
tors of 6 months MACE. The significance of the results was
assessed in the form of p-value differentiated into: non sig-
nificant when p-value >0.05, and significant when p-value
60.05.3. Results
3.1. Baseline characteristics and laboratory findings
Patients’ characteristics in the study subgroups are summa-
rized in Table 1. A total of 208 non diabetic patients with
STEMI were enrolled (mean age: 55.9 ± 7.12 years, 149 were
Table 3 Drugs on discharge.





Beta blocker 98 (88%) 81 (84%) 0.232
Aspirin 112 (100%) 96 (100%) 1.00
Clopidogrel 112 (100%) 96 (100%) 1.00
Statin 81 (73%) 74 (77%) 0.266
ACEI/ARBS 68 (61%) 63 (65%) 0.279
Diuretics 15 (13%) 17 (17.5%) 0.252
Nitrate 62 (55%) 59 (61%)0 0.211
Values are n (%). ACEI, angiotensine converting enzyme inhibi-
tors; ARBS, angiotensin receptors blockers.






Death 1 (0.89%) 1 (1.04%) 0.711
ST 0 1 (1.04%) 0.462
STEMI 0 1 (1.04%) 0.462
Non STEMI 0 1 (1.04%) 0.462
In hospital MACE 1 (0.89%) 2 (2.08%) 0.442
Values are n (%). ST, stent thrombosis; STEMI, st segment ele-
vation myocardial infarction; non STEMI, non st segment eleva-
tion myocardial infarction; MACE, major adverse cardiac events.






TLR 16 (14.29%) 38 (39.58%) <0.0001
Non-STEMI 3 (2.68%) 5 (5.21%) 0.279
STEMI 0 1 (1.04%) 0.462
ST 0 1 (1.04%) 0.462
Death 0 1 (1.04%) 0.462
Total MACE 17 (15.18%) 43 (44.79%) <0.001
Values are n (%). MACE, major adverse cardiac events; ST, stent
thrombosis; STEMI, st segment elevation myocardial infarction;
non STEMI, non st segment elevation myocardial infarction; TLR,
target lesion revascularization.
Table 6 Predictors of 6 months MACE by multivariate
analysis.
Variables HR 95% CI p-Value
HBA1c 1.9 1.2–3.4 0.022
EF 1.5 1.224–3.01 0.048
Time to reperfusion 0.5 0.358–0.925 0.011
Killip > 1 3.5 1.987–11.548 <0.001
HR, indicates hazard ratio; CI, confidence interval; EF, ejection
fraction.
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and 96 patients with prediabetes (group 2).
The baseline characteristics were generally similar in both
groups. The peak troponin level was similar in both groups
indicating that the infracted area was consistent.
3.2. Angiographic Data and interventional procedure outcome
Table 2 lists the baseline angiographic procedure and treat-
ment on discharge details. There was no significant difference
between the two groups regarding infarct related artery, pres-
ence of left main or three vessel disease, time to reperfusion,
thrombus aspiration use, and GPIIb/IIIa infusion. Also there
was no significant difference regarding stent deployment,
DES usage, stent length (SL) and stent diameter (SD).
The final angiographic results in the infarct related artery
were significantly better in group 1 as the achievement of final
TIMI 3 flow in the infarct related artery was significantly
higher in group 1 (87.5% vs 75%, p= 0.016), better MBG
(MBG II or III was 70.5% in group 1 vs 55% in group 2),
p= 0.003. On the other hand, angiographic no reflow was sig-
nificantly higher in group 2 (19.7% vs 7.14%, p= 0.006)
3.3. Medications at discharge
Dual antiplatelet therapy after PCI and prevalence of use of
other medications were similar among both groups Table 3.
3.4. In hospital clinical outcomes
The in- hospital outcome is shown in Table 4. One patient in
group 1 died due to post procedure cardiogenic shock becauseof extensive infarction. In group 2 one patient died because of
extensive anterior STEMI, urgent coronary angiography
showed acute stent thrombosis in LAD stent. Another patient
had non STEMI during planned PCI for non culprit RCA
lesion 72 h after the index procedure due to abrupt closure
of posterolateral branch.
3.5. Six months clinical outcome
After six months, the risk of MACE was higher for group 2
(p 6 0.001). The rate of death, STEMI, non STEMI and stent
thrombosis were similar in both groups. On the other hand,
the rate of target lesion revascularization was significantly
higher in group 2 (38 vs 16 p< 0.001). Out of the 16 patients
in group 1 who underwent TLR, 13 patients had exercise
induced angina and 3 patients developed non STEMI, How-
ever in group 2, 34 patients had exercise induced angina and
4 patients had non STEMI Table 5.
After multivariate Cox regression analysis for baseline
characteristics and angiographic findings, HbA1c was signifi-
cantly associated with 6 months clinical outcomes (hazard
ratio 1.9; 95% confidence interval 1.2–3.4; p= 0.022). Signif-
icant predictors are shown in Table 6.
4. Discussion
In the present study, 208 non diabetic STEMI patients treated
by PPCI were categorized into patients with normal glucose
tolerance and prediabetes patients according to the HbA1c
range recommended by ADA. The main findings of the present
study were as follows.
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had worse immediate angiographic outcome (TIMI
flow, MBG) and a higher risk of total MACE compared
with non diabetic patients with lower HbA1c level up to
six months follow up after primary PCI.
(2) The increased MACE risk was mainly due to higher risk
of target lesion revascularization (TLR) occurring
within six months.
(3) The risk of MI and stent thrombosis was similar among
non diabetic patients with low and high HbA1c level up
to six months.
HbA1c is associated with CHD risk among apparently
healthy, non diabetic women and men and it is an important
early clinical marker of disease risk [6].
In patients with STEMI without previously known dia-
betes, the acute glycometabolic response to stress in the early
phase was heterogeneous ranging from normal glucose level
to increase insulin resistance and hyperglycemia [18]. In previ-
ous studies hyperglycemia was associated with increased mor-
tality in STEMI patients [19–21]. However, hyperglycemia in
acute STEMI is not a reflection of previous glucose metabo-
lism but it represents the stress response to acute myocardial
injury and it is related to increased catecholamine release
[22,23]. HbA1c is a stable marker and reflects glucose metabo-
lism over the past 2–3 months. So, it is more accurate in assess-
ing the effect of abnormal glucose metabolism in non diabetics
with acute STEMI. However, there are conflicting results from
the available studies regarding the role of HbA1c in those
patients.
In a recent study, Pusuroglu et al. prospectively enrolled
443 consecutive patients with STEMI who underwent primary
PCI and they found a significant association between HbA1c
level and 1-year primary clinical outcomes, including CV mor-
tality, non-fatal reinfarction and stroke [24]. In agreement with
our results they found an increased rate of TLR and non fatal
MI in higher HbA1c groups.
In another observational study, 4176 STEMI non diabetic
patients treated by primary PCI by Timmer et al. [25], admis-
sion HbA1c was found to be associated with long-term mortal-
ity after adjusting for the other risk factors.
The authors of the 2 previous studies explained the
increased MACE rate in patients with higher HbA1c by the
increased baseline cardiovascular risks and worse angiographic
findings in patients with higher HbA1c level. However this was
not the case in our study as there was no significant difference
between patients with normal glucose metabolism and those
with prediabetes in baseline clinical characteristics and angio-
graphic findings. So, the increased MACE rate in our patients,
with elevated HbAIc, particularly TLR, might be due to the
adverse effect of the chronic abnormal glucose metabolism in
those patients.
Chronic hyperglycemia, even below the threshold for diag-
nosis of diabetes, has adverse effect on platelet function, coag-
ulation cascade, endothelial function and is associated with
increased fibrinogen levels [26]. It also affects the ischemic cell
metabolism, inflammation and apoptosis [27,28]. All these fac-
tors are associated with worse outcome and increased mortal-
ity in ACS patients as reported by Deedwania et al. [29]. This
could explain why patients with prediabetes in this study had
worse immediate angiographic outcome regarding TIMI flow,
MBG and angiographic no reflow.On the other hand, different results were recently reported
by Tian et al. [30] who prospectively enrolled 607 patients with
STEMI treated by primary PCI and they stratified the patients
according to HbA1c into 3 groups: (I) HbA1c 5.6% or less
(n= 262); (II), HbA1c 5.7–6.4% (n= 182); and (III), HbA1c
at least 6.5% (n= 164). The 7-d mortality was similar
(p= 0.179) between groups I (1.9%), II (2.2%) and III
(0.0%) as well as the 30-day mortality (p= 0.241) between
groups I (3.8%), II (2.2%), and III (1.2%). Major adverse car-
diac events at the 7-day and 30-day follow-up were not signif-
icantly different between the three groups either (p> 0.05).
After adjusting the baseline characteristics, HbA1c was not
an independent predictor of short-term outcomes
(HR= 0.431; 95% CI: 0.175–1.061, p= 0.067). Similar
results were reported in another 2 studies where HbA1c was
shown not to be a prognostic factor associated with 30-day
mortality [31,32].
The reason why these studies failed to show significant
prognostic value for HbA1c may be due to the fact that short
time MACE in STEMI patients is related to reperfusion time,
infarct size and other short term complications, whereas the
abnormal glucose metabolism, represented by higher HbA1c,
needs a longer time to manifest.
4.1. Study limitation
This is a single center study with a relatively small number of
patients. Another limitation is the probability that some of the
patients in the prediabetes group may have progressed to overt
clinical diabetes mellitus during the six month follow up period
and this could affect the clinical follow up.5. Conclusion
Abnormal glycometabolic state assessed by HbA1c at admis-
sion in non diabetic STEMI patients is associated with higher
MACE incidence at 6 months follow up mainly due to higher
incidence of TLR. This finding could raise a question about
the effect of elevation of blood glucose level below the detec-
tion limit of diabetes on the PPCI outcome and indicates that
routine measures of admission HbA1c in STEMI patients
could improve clinical outcome by early detection of patients
who need close follow up and better glycometabolic control.
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